As the global demographic evolves, the challenge of menopause confronts a growing number of women. This inevitable transition is often accompanied by a myriad of distressing side effects. Although hormone-replacement therapy offers some relief, its severe side effects render it a less-than-ideal solution. Recognizing this unmet need, our iGEM research sowed the seeds for Equolity Bio, with a vision to revolutionize menopause treatment using equol.
Equol, a promising phytoestrogen, mirrors the effects of estrogen in the human body. However, current extraction methods make it prohibitively expensive, with effective doses priced at an eye-watering $40,000. Our innovative solution employs specific bacteria to produce equol from daidzein, making it both scalable and affordable.
While our iGEM team remains immersed in research, pushing boundaries and uncovering new possibilities, our entrepreneurial spirit thrives parallelly. We've presented our groundbreaking idea across esteemed platforms and competitions, securing significant funding from:
These accolades are not just financial catalysts but represent the interdisciplinary trust and enthusiasm for our mission. This blend of academic research and entrepreneurial spirit puts us in a unique position, combining rigorous science with real-world impact.
We recognize the significant need in the women's health sector and are actively working to address it. While our primary focus is on delivering a reliable solution for menopause symptoms, we're also conscious of the environmental implications of our methods and aim for sustainable processes.
Equolity’s mission is straightforward: to improve the quality of life for women experiencing menopause. We believe that with dedicated research and a clear focus, we can make a meaningful difference.
Watch our presentation at Startup Yale 2023 Rita Wilson Pitch (where Hassaan Qadir, Yale 2022 Team member and current Yale iGEM Mentor, presented to investors and judges.)